Cite
MLA Citation
B. Besse et al.. “Update from the ongoing phase 1/2 registrational trial of repotrectinib: results in TKI-naïve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1).” European journal of cancer, vol. 174, n.d., pp. S75–S76. http://access.bl.uk/ark:/81055/vdc_100168600366.0x000049